Tag - ANIX

Anixa Biosciences (NASDAQ:ANIX) reported that its partner, Cleveland Clinic, received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application covering the company’s ovarian cancer...

Anixa Biosciences (NASDAQ:ANIX) and its partner, Cleveland Clinic, presented positive new results from the Phase 1 clinical trial of Anixa’s breast cancer vaccine at the 2023 San Antonio Breast Cancer Symposium (SABCS)...

Anixa Biosciences (NASDAQ:ANIX) reported that its partner, Cleveland Clinic, received an intention-to-grant notice from the European Patent Office (EPO) for the patent application covering the company’s ovarian cancer...

Anixa Biosciences (NASDAQ:ANIX) appointed Dr. Mark Goldberg as the ninth independent member of the company’s Cancer Business Advisory Board (CBAB). “Mark brings valuable clinical expertise in oncology, and his extensive...

Anixa Biosciences (NASDAQ:ANIX), in partnership with Moffitt Cancer Center, completed treatment of the first patient cohort in the ongoing clinical trial of Anixa’s novel chimeric antigen receptor T-cell (CAR-T) therapy...

Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine was featured in an Oct. 3 article in Yahoo Life news. The article introduces Ohioan Jennifer Davis as the first person in the world to receive a breast cancer...

Anixa Biosciences (NASDAQ:ANIX) formed a cancer business advisory board (CBAB) with a roster of renowned cancer advocates, executives and physicians to guide the company’s clinical and business development...

Anixa Biosciences (NASDAQ:ANIX), in partnership with Moffitt Cancer Center, commenced treatment of the third patient in the ongoing clinical trial of Anixa’s novel chimeric antigen receptor T-cell (CAR-T) therapy...

Dr. Pamela Garzone, chief development officer of Anixa Biosciences (NASDAQ:ANIX) will present, “Developing a CAR-T for Ovarian Cancer and Other Solid Tumors,” at the 8th Annual CAR-TCR Summit in Boston...

Anixa Biosciences’ (NASDAQ:ANIX) partner, Cleveland Clinic, has begun enrolling subjects in a treatment arm evaluating the combination of the company’s breast cancer vaccine with Keytruda. The treatment arm is an...